Literature DB >> 23564067

Restoration of wild-type p53 in drug-resistant mouse breast cancer cells leads to differential gene expression, but is not sufficient to overcome the malignant phenotype.

Benjamin Gottschalk1, Andreas Klein.   

Abstract

We established a breast cancer cell line from a fast growing mouse WAP-SVT/t breast tumor. Cells from this line, SVTneg2, switched off T-antigen expression, carry a missense mutation at the p53 codon 242 (mouse G242 corresponds to human hot spot mutation G245), are malignantly transformed, highly aneuploid and very insensitive to apoptotic stimuli. To examine the influence of wild-type p53 (wtp53) restoration on the behavior of the SVTneg2 cells, we transfected these cells with wtp53 and generated three permanent cell lines expressing wtp53. Interestingly, restoration of p53 had no influence on chemotherapy sensitivity and the transformation capacity of these breast cancer cells, but markedly changed the gene expression of wtp53-dependent genes after doxorubicin treatment. We postulate that restoration of p53 leads to massive changes in gene expression and to a reduced proliferation rate, but is not sufficient to overcome the malignant phenotype and the chemoresistance of SVTneg2.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23564067     DOI: 10.1007/s11010-013-1643-5

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  76 in total

Review 1.  p63/p73 in the control of cell cycle and cell death.

Authors:  N Allocati; C Di Ilio; V De Laurenzi
Journal:  Exp Cell Res       Date:  2012-02-03       Impact factor: 3.905

2.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

3.  An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control.

Authors:  A Gualberto; K Aldape; K Kozakiewicz; T D Tlsty
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

4.  Prognostic significance of p53 mutations in colon cancer at the population level.

Authors:  Wade S Samowitz; Karen Curtin; Khe-ni Ma; Sandra Edwards; Donna Schaffer; Mark F Leppert; Martha L Slattery
Journal:  Int J Cancer       Date:  2002-06-01       Impact factor: 7.396

5.  p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes.

Authors:  M Dohn; S Zhang; X Chen
Journal:  Oncogene       Date:  2001-05-31       Impact factor: 9.867

6.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

7.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

8.  ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation.

Authors:  Ester M Hammond; Mary Jo Dorie; Amato J Giaccia
Journal:  J Biol Chem       Date:  2003-01-07       Impact factor: 5.157

9.  Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

Authors:  Shunsuke Kato; Shuang-Yin Han; Wen Liu; Kazunori Otsuka; Hiroyuki Shibata; Ryunosuke Kanamaru; Chikashi Ishioka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 11.205

10.  Comparative analysis of p73 and p53 regulation and effector functions.

Authors:  L Fang; S W Lee; S A Aaronson
Journal:  J Cell Biol       Date:  1999-11-15       Impact factor: 10.539

View more
  1 in total

1.  Inositol-C2-PAF acts as a biological response modifier and antagonizes cancer-relevant processes in mammary carcinoma cells.

Authors:  Carsten Pelz; Sonja Häckel; Geo Semini; Sandra Schrötter; Willem Bintig; Sebastian Stricker; Gudrun Mrawietz; Andreas Klein; Lothar Lucka; Vadim Shmanai; Britta Eickholt; Annette Hildmann; Kerstin Danker
Journal:  Cell Oncol (Dordr)       Date:  2018-07-25       Impact factor: 6.730

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.